Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Doritchamou, J, Bigey, P, Nielsen, MA, Gnidehou, S, Ezinmegnon, S, Burgain, A, Massougbodji, A, Deloron, P, Salanti, A & Ndam, NT 2013, 'Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA', Vaccine, vol. 31, no. 41, pp. 4516-22. https://doi.org/10.1016/j.vaccine.2013.07.072

APA

Doritchamou, J., Bigey, P., Nielsen, M. A., Gnidehou, S., Ezinmegnon, S., Burgain, A., Massougbodji, A., Deloron, P., Salanti, A., & Ndam, N. T. (2013). Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. Vaccine, 31(41), 4516-22. https://doi.org/10.1016/j.vaccine.2013.07.072

CBE

MLA

Vancouver

Author

Doritchamou, Justin ; Bigey, Pascal ; Nielsen, Morten Agertoug ; Gnidehou, Sédami ; Ezinmegnon, Sem ; Burgain, Aurore ; Massougbodji, Achille ; Deloron, Philippe ; Salanti, Ali ; Ndam, Nicaise Tuikue. / Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. In: Vaccine. 2013 ; Vol. 31, No. 41. pp. 4516-22.

Bibtex

@article{cd39a44511f7475387a4ba2f2e3d3d0c,
title = "Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA",
abstract = "VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.",
author = "Justin Doritchamou and Pascal Bigey and Nielsen, {Morten Agertoug} and S{\'e}dami Gnidehou and Sem Ezinmegnon and Aurore Burgain and Achille Massougbodji and Philippe Deloron and Ali Salanti and Ndam, {Nicaise Tuikue}",
year = "2013",
month = sep,
day = "23",
doi = "10.1016/j.vaccine.2013.07.072",
language = "English",
volume = "31",
pages = "4516--22",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier Ltd",
number = "41",

}

RIS

TY - JOUR

T1 - Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA

AU - Doritchamou, Justin

AU - Bigey, Pascal

AU - Nielsen, Morten Agertoug

AU - Gnidehou, Sédami

AU - Ezinmegnon, Sem

AU - Burgain, Aurore

AU - Massougbodji, Achille

AU - Deloron, Philippe

AU - Salanti, Ali

AU - Ndam, Nicaise Tuikue

PY - 2013/9/23

Y1 - 2013/9/23

N2 - VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.

AB - VAR2CSA is a large polymorphic Plasmodium falciparum protein expressed on infected erythrocytes (IE) that allows their binding in the placenta, thus precipitating placental malaria (PM). The N-terminal part of VAR2CSA that contains the binding site to placental chondroitin sulfate A (CSA) is currently recognized as the most attractive region for vaccine development. An ultimate challenge is to define epitopes in this region that induce a broad cross-reactive adhesion inhibitory antibody response.

U2 - 10.1016/j.vaccine.2013.07.072

DO - 10.1016/j.vaccine.2013.07.072

M3 - Journal article

C2 - 23933341

VL - 31

SP - 4516

EP - 4522

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 41

ER -

ID: 41633874